TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32014382

Group type: EXPERIMENTAL
Intervention: StepEase™ diabetic socks
Number of subjects: 31
Study: 36471403

Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA) intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Active Control
Number of subjects: 120
Study: 32381573

Group type: EXPERIMENTAL
Intervention: Low B cell count
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: T cell, macrophage, and Hodgkin-Reed-Sternberg-cell content
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Low B cell content
Number of subjects: 340
Study: 32897298

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36357016

Group type: EXPERIMENTAL
Intervention: Amulet device (dual occlusive mechanism)
Number of subjects: 1593

Group type: COMPARATOR
Intervention: Watchman 2.5 device (single occlusive mechanism)
Number of subjects: 1593

Group type: EXPERIMENTAL
Intervention: Peridevice leak (PDL) ≥3 mm
Number of subjects: 1593
Study: 32993731

Group type: EXPERIMENTAL
Intervention: EUS-HGS
Number of subjects: 148

Group type: COMPARATOR
Intervention: EUS-AG
Number of subjects: 148
Study: 36330670

Group type: EXPERIMENTAL
Intervention: Block group (collagenated soft-block-type BCP)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Particle group (particulate BCP)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups (regardless of BCP type)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study: 34001462

Group type: EXPERIMENTAL
Intervention: Short-course radiation therapy (SCRT) followed by chemotherapy (FOLFOX ×8 or CAPOX ×5 cycles)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Short-course radiation therapy (SCRT) followed by chemotherapy
Number of subjects: 19
Study: 32736184

Group type: EXPERIMENTAL
Intervention: Antidepressant trials
Number of subjects: 179
Study: 34037955

Group type: EXPERIMENTAL
Intervention: Aerobic exercise for 30 min per session, 5 times a week for 6 weeks with conventional treatment
Number of subjects: 112

Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 112

Group type: COMPARATOR
Intervention: Comparison of aerobic exercise plus conventional treatment vs. conventional treatment alone
Number of subjects: 112
Study: 32617694

Group type: EXPERIMENTAL
Intervention: 2-day SDD group
Number of subjects: 447

Group type: COMPARATOR
Intervention: 3-day SDD group
Number of subjects: 447
Study: 35401732

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (in addition to escitalopram oxalate)
Number of subjects: 118
Study: 33782715

Group type: EXPERIMENTAL
Intervention: Heat-and-moisture-exchanging mask (HME) during time-trial (TT)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Heat-and-moisture-exchanging mask (HME) during submaximal warm-up (SUB)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Heat-and-moisture-exchanging mask (HME) during SUB
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Heat-and-moisture-exchanging mask (HME)
Number of subjects: 23
Study: 34077745

Group type: EXPERIMENTAL
Intervention: Topical betamethasone eye drops
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no preoperative betamethasone)
Number of subjects: 62
Study: 34551229

Group type: EXPERIMENTAL
Intervention: Tebentafusp
Number of subjects: 378

Group type: COMPARATOR
Intervention: Control (investigator's choice of therapy with single-agent pembrolizumab, ipilimumab, or dacarbazine)
Number of subjects: 378
Study: 35799239

Group type: EXPERIMENTAL
Intervention: Lactulose monotherapy
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: S. boulardii monotherapy
Number of subjects: 187
Study: 35372900

Group type: EXPERIMENTAL
Intervention: ISD/HY
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 35489037

Group type: EXPERIMENTAL
Intervention: 0.3% chlorhexidine gluconate vaginal preparation
Number of subjects: 240

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 240
Study: 35145853

Group type: EXPERIMENTAL
Intervention: SP‐TCM training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional‐method training
Number of subjects: 0
Study: 33065358

Group type: EXPERIMENTAL
Intervention: Fostering Changes program
Number of subjects: 26

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 26
Study: 36235848

Group type: EXPERIMENTAL
Intervention: Feedback e‐12HR application (intervention group)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Non-feedback e‐12HR application (control group)
Number of subjects: 286
Study: 34022790

Group type: EXPERIMENTAL
Intervention: Three antihypertensive regimens for 6 months
Number of subjects: 721

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 721
Study: 32773308

Group type: COMPARATOR
Intervention: Control calf starter (CS) with conventional soybean meal (SBM) as the main source of protein (CTRL)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Isonitrogenous (20% CP) CS with enzyme‐treated SBM as the main source of protein (ENZT)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: CS with low content of CP (10%) and no soy protein (LOCP)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: HICP diets (high-protein diets)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: ENZT diet (enzyme-treated SBM)
Number of subjects: 3
Study: 34151874

Group type: EXPERIMENTAL
Intervention: Customized vestibular rehabilitation plus standard canalith repositioning maneuver (CRM) for six weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard canalith repositioning maneuver (CRM) for two weeks
Number of subjects: 28
Study: 34528761

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) screening
Number of subjects: 4664

Group type: COMPARATOR
Intervention: No LDCT screening
Number of subjects: 4664
Study: 33734750

Group type: EXPERIMENTAL
Intervention: Not sure option: yes
Number of subjects: 2724

Group type: COMPARATOR
Intervention: Not sure option: no
Number of subjects: 2724
Study: 32491006

Group type: EXPERIMENTAL
Intervention: C30 (30% load)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: C60 (60% load)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 33559212

Group type: EXPERIMENTAL
Intervention: Body shape pattern group (selection based on observed body shape indices, BMI, and sex)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (traditional dorsogluteal injection)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Anthropometric indices group (selection based on BMI, waist circumference, and ASIS-IT)
Number of subjects: 162
Study: 32694638

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 103
Study: 35759049

Group type: EXPERIMENTAL
Intervention: Nutrition counseling plus logotherapy (n=46)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Nutrition counseling alone (n=44)
Number of subjects: 90
Study: 34176795

Group type: EXPERIMENTAL
Intervention: Home safety supervisory program (HSSP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Teaching on child care (Control)
Number of subjects: 0
Study: 32041859

Group type: EXPERIMENTAL
Intervention: Autologous osteoperiosteal cylinder graft transplantation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Autologous osteochondral transplantation
Number of subjects: 70
Study: 35902298

Group type: EXPERIMENTAL
Intervention: Carryover voice therapy using carryover strategies
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Traditional voice therapy with no emphasis on generalizing process
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Carryover voice therapy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Controls (eight-week non-therapy period)
Number of subjects: 53
Study: 32751170

Group type: EXPERIMENTAL
Intervention: 28 g of rapeseed protein isolate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Soy protein isolate (control)
Number of subjects: 20
Study: 36096353

Group type: EXPERIMENTAL
Intervention: Standard Facebook group (n = 60)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Professional-led Facebook group (n = 59)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Both conditions (Standard and Professional-led)
Number of subjects: 119
Study: 33947346

Group type: EXPERIMENTAL
Intervention: TMCP approach used by clinicians
Number of subjects: 8198

Group type: EXPERIMENTAL
Intervention: AAC + TMCP
Number of subjects: 8198

Group type: COMPARATOR
Intervention: AAC only
Number of subjects: 8198
Study: 32105268

Group type: EXPERIMENTAL
Intervention: Recognan (citicoline), 100 mg in 1 ml, taken orally for 30 days (daily dosage of 0.5 g).
Number of subjects: 38

Group type: COMPARATOR
Intervention: Comparison group (no medication).
Number of subjects: 38
Study: 36224294

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Linagliptin 5 mg
Number of subjects: 0
Study: 33409777

Group type: EXPERIMENTAL
Intervention: Model 1 incorporating selected morphological and clinical features
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Model 2 incorporating selected texture and clinical features
Number of subjects: 205

Group type: COMPARATOR
Intervention: High-grade serous carcinoma (HGSC)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Both models
Number of subjects: 205
Study: 35990057

Group type: EXPERIMENTAL
Intervention: taVNS combined with electroacupuncture (8 weeks, 3 sessions per week for taVNS; 8 weeks, twice per day for electroacupuncture)
Number of subjects: 60

Group type: COMPARATOR
Intervention: citalopram (8 weeks, 40 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: citalopram
Number of subjects: 60
Study: 33861432

Group type: EXPERIMENTAL
Intervention: Curcumin supplement (500 mg daily for 12 weeks)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 66
Study: 32748072

Group type: EXPERIMENTAL
Intervention: Charisma resin composite restorations
Number of subjects: 40

Group type: COMPARATOR
Intervention: Charisma Classic resin composite restorations
Number of subjects: 40
Study: 32305184

Group type: EXPERIMENTAL
Intervention: Beating heart simulator training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonbeating heart simulator training
Number of subjects: 60
Study: 32474935

Group type: EXPERIMENTAL
Intervention: Platform-switching (PS) implants
Number of subjects: 18

Group type: COMPARATOR
Intervention: Platform-matching (PM) implants
Number of subjects: 18
Study: 35921357

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: IVF (In Vitro Fertilization)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cost-effective profile of surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cost-effective profile of IVF
Number of subjects: 100
Study: 32540986

Group type: EXPERIMENTAL
Intervention: DOSE HPV intervention (7-session program including provider education, communication training, data feedback, and tailored systems change)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: DOSE HPV intervention
Number of subjects: 5
Study: 33503045

Group type: EXPERIMENTAL
Intervention: Prosocial behavior intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-focused behavior
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral behavior
Number of subjects: 0
Study: 32086901

Group type: EXPERIMENTAL
Intervention: Nasal spray allergen blocker combined with azelastine hydrochloride nasal spray
Number of subjects: 84

Group type: COMPARATOR
Intervention: Azelastine hydrochloride nasal spray
Number of subjects: 84
Study: 33621541

Group type: EXPERIMENTAL
Intervention: ticagrelor plus aspirin (DAPT)
Number of subjects: 3486

Group type: COMPARATOR
Intervention: ticagrelor plus matching placebo (SAPT)
Number of subjects: 3486

Group type: EXPERIMENTAL
Intervention: IVUS-guided DES implantation
Number of subjects: 3486

Group type: COMPARATOR
Intervention: Angiography-guided DES implantation
Number of subjects: 3486
Study: 36327527

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) Q3W for four cycles with once-daily cabozantinib (40 mg), then nivolumab (240 mg) Q2W plus once-daily cabozantinib (40 mg)
Number of subjects: 50
Study: 35597972

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy/Motivational Interviewing (CBT/MI) intervention, administered in six sessions over 3 months.
Number of subjects: 20
Study: 32141054

Group type: EXPERIMENTAL
Intervention: Coffee consumption (3 cups after cesarean)
Number of subjects: 103

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 103
Study: 33574070

Group type: EXPERIMENTAL
Intervention: reconstructed chest radiograph (r-CXR)
Number of subjects: 300

Group type: COMPARATOR
Intervention: high-resolution CT (HRCT)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: r-CXR
Number of subjects: 300

Group type: COMPARATOR
Intervention: CT
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: r-CXR and HRCT
Number of subjects: 300
Study: 32706937

Group type: EXPERIMENTAL
Intervention: Ribociclib 600-mg tablet
Number of subjects: 94

Group type: COMPARATOR
Intervention: Ribociclib 600-mg capsule
Number of subjects: 94

Group type: COMPARATOR
Intervention: Ribociclib intravenous infusion 150 mg
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Ribociclib oral administration
Number of subjects: 94

Group type: COMPARATOR
Intervention: Ribociclib 600-mg tablet and capsule
Number of subjects: 94
Study: 36162958

Group type: EXPERIMENTAL
Intervention: Nebulisation using NHF
Number of subjects: 33

Group type: COMPARATOR
Intervention: Nebulisation using JN
Number of subjects: 33
Study: 34086067

Group type: EXPERIMENTAL
Intervention: HLX04 (3 mg/kg intravenous infusion)
Number of subjects: 208

Group type: COMPARATOR
Intervention: HLX04 and reference bevacizumab
Number of subjects: 208
Study: 32785654

Group type: EXPERIMENTAL
Intervention: Sprint interval training or moderate-intensity continuous training for two weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (sedentary, no exercise training)
Number of subjects: 54
Study: 36121700

Group type: EXPERIMENTAL
Intervention: PCI with everolimus-eluting stents
Number of subjects: 880

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 880
Study: 33287685

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT), 4 sessions of 1 hour
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 60
Study: 36219596

Group type: EXPERIMENTAL
Intervention: Personalised self-management support co-designed with participants
Number of subjects: 45

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 45
Study: 34134828

Group type: EXPERIMENTAL
Intervention: D‐cycloserine augmented ERP
Number of subjects: 161

Group type: COMPARATOR
Intervention: Pill placebo augmented ERP
Number of subjects: 161
Study: 33106696

Group type: EXPERIMENTAL
Intervention: Oral care
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control
Number of subjects: 61
Study: 34580975

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Glimepiride 1 mg
Number of subjects: 23
Study: 34529768

Group type: EXPERIMENTAL
Intervention: ATRA plus arsenic trioxide (ATO)
Number of subjects: 161

Group type: COMPARATOR
Intervention: ATRA chemotherapy
Number of subjects: 161
Study: 33284672

Group type: EXPERIMENTAL
Intervention: Body diversity intervention
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Thin-ideal intervention
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study: 32375840

Group type: EXPERIMENTAL
Intervention: Sugira Muryango
Number of subjects: 541
Study: 35123070

Group type: EXPERIMENTAL
Intervention: Octreotide acetate pen injector
Number of subjects: 45
Study: 35580203

Group type: EXPERIMENTAL
Intervention: Routine manual aspiration thrombectomy
Number of subjects: 2869
Study: 34943854

Group type: EXPERIMENTAL
Intervention: HIFU ablation of primary cancer followed by modified radical mastectomy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (modified radical mastectomy only)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: HIFU group
Number of subjects: 48
Study: 36152268

Group type: EXPERIMENTAL
Intervention: anti-HBc level <325 IU/ml
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: anti-HBc level ≥325 IU/ml
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Combination of anti-HBc <325 IU/ml with HBsAg >3008 IU/ml
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Combination of anti-HBc <325 IU/ml with HBcrAg ≥1790 U/ml
Number of subjects: 136
Study: 33821793

Group type: EXPERIMENTAL
Intervention: Physiological glucocorticoid exposure
Number of subjects: 10

Group type: COMPARATOR
Intervention: Withdrawal from glucocorticoid exposure
Number of subjects: 10
Study: 35513720

Group type: EXPERIMENTAL
Intervention: TMS‐transspinal paired with locomotor training
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: transspinal‐TMS paired with locomotor training
Number of subjects: 8
Study: 33406892

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (5 days a week for 8 weeks, consisting of six sets of 30 breaths per day with a training load ≥50% of maximal inspiratory pressure)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (only received the educational program)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 39

Group type: COMPARATOR
Intervention: Inspiratory muscle training and Control group
Number of subjects: 39
Study: 34247614

Group type: EXPERIMENTAL
Intervention: Community empowerment intervention including a community-led drop-in-center, venue-based peer education, condom distribution, HIV testing, peer service navigation, sensitivity trainings, and text messages to promote engagement.
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Attendance at the Shikamana drop-in-center.
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Attendance at a family planning-related workshop.
Number of subjects: 339
Study: 35696397

Group type: EXPERIMENTAL
Intervention: Functional Gastrointestinal Disorders (FGIDs)
Number of subjects: 860

Group type: EXPERIMENTAL
Intervention: Functional Dyspepsia (FD)
Number of subjects: 860

Group type: EXPERIMENTAL
Intervention: Functional Heartburn
Number of subjects: 860

Group type: EXPERIMENTAL
Intervention: Functional Bloating
Number of subjects: 860

Group type: EXPERIMENTAL
Intervention: Overlapping disorders
Number of subjects: 860

Group type: EXPERIMENTAL
Intervention: Psychosocial alarm symptoms
Number of subjects: 860

Group type: EXPERIMENTAL
Intervention: Victimization
Number of subjects: 860
Study: 34413443

Group type: EXPERIMENTAL
Intervention: Detection by trained dogs in laboratory conditions
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Detection by trained dogs in semi-field conditions
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Detection by trained dogs in standardized field conditions
Number of subjects: 2
Study: 32114513

Group type: EXPERIMENTAL
Intervention: Chemotherapy with bevacizumab
Number of subjects: 227
Study: 36258168

Group type: EXPERIMENTAL
Intervention: Padres Preparados, Jóvenes Saludables program (8 weekly sessions of 2.5 hours each)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group (delayed-treatment)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Fathers' sugar-sweetened beverage (SSB) intake
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Fathers' fast food intake
Number of subjects: 147
Study: 34019540

Group type: EXPERIMENTAL
Intervention: Free distribution of essential medicines (n = 395)
Number of subjects: 786

Group type: COMPARATOR
Intervention: Usual medicine access (n = 391)
Number of subjects: 786
Study: 32141343

Group type: EXPERIMENTAL
Intervention: Ateos
Number of subjects: 48

Group type: COMPARATOR
Intervention: FlexTouch
Number of subjects: 48
Study: 36030464

Group type: EXPERIMENTAL
Intervention: S-ICD
Number of subjects: 849

Group type: COMPARATOR
Intervention: TV-ICD
Number of subjects: 849
Study: 33049918

Group type: EXPERIMENTAL
Intervention: SVF combined with β‐TCP
Number of subjects: 0

Group type: COMPARATOR
Intervention: β‐TCP alone (Control)
Number of subjects: 0
Study: 36129708

Group type: EXPERIMENTAL
Intervention: Nonpharmacologic interventions including earplugs, eye mask, aromatherapy, and postponed morning medication and vital sign measurement rounds.
Number of subjects: 374

Group type: COMPARATOR
Intervention: Control group received usual care without nonpharmacologic interventions.
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Both groups reported main sleep-disturbing factors: noises, pain, toilet visits, and being awakened by hospital staff.
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Intervention group with postponed vital sign checks and medication rounds.
Number of subjects: 374
Study: 33635604

Group type: EXPERIMENTAL
Intervention: Cognitive function (measured by Mini Mental State Exam)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Independence of self-feeding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nurse support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General self-care capacity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Appetite the week before
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regression model
Number of subjects: 0
Study: 32043980

Group type: EXPERIMENTAL
Intervention: Local excision
Number of subjects: 145

Group type: COMPARATOR
Intervention: Total mesorectal excision
Number of subjects: 145
Study: 33177349

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) combo therapy
Number of subjects: 122
Study: 34018375

Group type: COMPARATOR
Intervention: Conventional MRI
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: MRI after vaginal filling with ultrasound gel
Number of subjects: 158
Study: 34234262

Group type: EXPERIMENTAL
Intervention: Subcapsular castration (SC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Open castration (OC)
Number of subjects: 12
Study: 32176792

Group type: EXPERIMENTAL
Intervention: Linezolid administered intravenously at a standard dose of 600 mg every 12 hours with CVVH
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Linezolid administered intravenously at a standard dose of 600 mg every 12 hours with EDH
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard 600 mg intravenous administration every 12 hours
Number of subjects: 20
Study: 36440217

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Whole-body vibration (WBV) and Resistance exercise (RE)
Number of subjects: 10